You can buy or sell LXRX and other stocks, options, ETFs, and crypto commission-free!
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. Read More The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
The Woodlands, Texas
52 Week High
52 Week Low
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm
NEW YORK, NY / ACCESSWIRE / March 26, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Lexicon Pharmaceuticals, Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - LXRX
NEW YORK, NY / ACCESSWIRE / March 26, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against Lexicon Pharmaceuticals, Inc.
Yahoo FinanceMar 25
Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug
Shares of Lexicon Pharmaceuticals, Inc. LXRX plunged almost 22% on Mar 22 following a complete response letter (“CRL”) to the new drug application (“NDA”) seeking approval of its lead pipeline candidate, Zynquista (sotagliflozin). Lexicon is developing the candidate in collaboration with Sanofi SNY. Zynquista is a dual SGLT1 and SGLT2 inhibitor evaluated in combination with insulin for the treatment of type I diabetes in adult patients. Lexicon’s shares have decreased 6.6% so far this year against the ind...
-$0.29 per share
-$0.16 per share